Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 57 % of short-term debt in 2026; threshold 65 %.
Financials
Financial year 2026
ETIS PHARMA from Pont-à-Celles, company number BE0702914656, closed financial year 2026 with a result of € 21,250 after tax. For that financial year ETIS PHARMA recorded a gross margin of € 259,449 and equity of € 18,611. Compared with financial year 2025, the result moved from € 2,116 to € 21,250. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 7, 2026.
€ 18,611
▼ 10% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 21,250
▲ € 19,134 vs 2025
Profit after tax over the fiscal year.
€ 135,878
▲ 52% vs 2025
Cash and bank balances on the last day of the fiscal year.
€ 23,400 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2026
3.5
▲ 0.4 vs 2025
Average over the fiscal year, from the social balance sheet.
€ 175,864
▲ 12% vs 2025
€ 50,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 14,268
▼ 40% vs 2025
Of which on lease € 727.
Debts at end 2026
€ 250,268
▼ 14% vs 2025
€ 38,574 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 210,903
▲ 4% vs 2025
Supplier invoices still open on the last day of the fiscal year.
€ 32,199
▲ 31% vs 2025
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € 236,870 | € 241,102 | € 217,947 | € 259,449 | ▲ 19% |
| Profit after taxes | € 47,046 | € 38,733 | € 2,116 | € 21,250 | ▲ € 19,134 |
| Equity | € 191,879 | € 143,946 | € 20,761 | € 18,611 | ▼ 10% |
| Total debts | € 567,721 | € 527,283 | € 596,886 | € 580,755 | ▼ 3% |
| Cash | € 147,056 | € 120,342 | € 89,440 | € 135,878 | ▲ 52% |
| Land & buildings | € 265,513 | € 250,626 | € 237,684 | € 219,944 | ▼ 7% |
| Retained profit | € 173,279 | € 125,346 | € 2,161 | € 11 | ▼ € 2,151 |
| Dividend | € 0 | € 86,667 | € 125,300 | € 23,400 | ▼ 81% |
| Bank debt | € 369,905 | € 335,509 | € 291,257 | € 250,268 | ▼ 14% |
| Balance sheet total | € 759,600 | € 671,229 | € 617,647 | € 599,365 | ▼ 3% |
| Employees (FTE) | 2.3 | 2.6 | 3.1 | 3.5 | ▲ 0.4 |
Key figures of ETIS PHARMA, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 August 2027.
What happened to ETIS PHARMA?
What happened at ETIS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 21,250 (▲ € 19,134 vs 2025). Source: NBB ↗
- New establishment in Pont-à-Celles. KBO
- Start of the company according to the CBE. KBO
In short
From € 47,046 profit in 2023 to € 21,250 profit in 2026.
Paid € 29,071 in corporate taxes since 2023.
Best year ever: 2023, with € 47,046 profit.
On average € 74,100 of value added per employee in 2026.
A new publication or filing at ETIS PHARMA? We notify you, reason included.
Follow ETIS PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2026 annual accounts
Etienne EVRARD
Administrator-manager
Establishments
Establishment units
Physical locations of this company
Place du Marais(PAC) 2
6230 Pont-à-Celles
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0702.914.656
- VAT number
- BE 0702.914.656
- Registered office
- Place du Marais(PAC) 2, 6230 Pont-à-Celles
- Names & denominations
- ETIS PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 September 2018
- Peppol
- Active · Active since 6 Aug 2025
- Activities · NACE
Detailhandel in farmaceutische producten